share_log

HC Wainwright & Co. Reiterates Buy on Karyopharm Therapeutics, Maintains $8 Price Target

HC Wainwright & Co. Reiterates Buy on Karyopharm Therapeutics, Maintains $8 Price Target

HC Wainwright & Co.重申买入Karyopharm Therapeutics,维持8美元的目标股价
Benzinga ·  05/09 06:53

HC Wainwright & Co. analyst Edward White reiterates Karyopharm Therapeutics (NASDAQ:KPTI) with a Buy and maintains $8 price target.

HC Wainwright & Co. 分析师爱德华·怀特重申Karyopharm Therapeutics(纳斯达克股票代码:KPTI)的买入并维持8美元的目标股价。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发